Sareum - Specialists in Cancer Drug Discovery
Print the page Smaller text Larger text


Research Update & Co-Development Collaborations
26 February, 2014

Half-yearly Report
26 February, 2014

CHK1 Patent Update
22 January, 2014

Issue of Options
19 December, 2013

Result of Annual General Meeting
11 December, 2013

RSS news feed News feed
requires RSS news reader

Sareum Holdings
Last Trading 0.45
Trade Time 16:16am
Change -0.02
Open 0.48
Day's Range 0.4505 - 0.50
Volume 6108801


Sareum's small molecule drug discovery expertise is building value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies


Providing protein structure-based research services to accelerate customers’ drug discovery programmes
Developing oncology drug candidates for licensing to pharmaceutical companies


Learn more about Sareum’s pipeline of targeted small molecule drug candidates

Annual Report & Accounts 2013 can be downloaded from our Information page. AGM notice & voting form can be downloaded here

                                                                                            Website last updated on: 22-Jan-2014



Requires RSS news reader

Requires MS Word

Requires Adobe Acrobat Reader

site map

cookie policy

email: info (at) tel: +44 (0) 1223 497700 fax: +44 (0) 1223 497701